Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

Merck MRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.